Dulaglutide vs Survodutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Trulicity
Dulaglutide (brand name Trulicity) is a once-weekly injectable GLP-1 receptor agonist made by fusing a modified GLP-1 peptide to a fragment of a human antibody, which is what lets it last a full week between shots. It is FDA-approved for type 2 diabetes and, notably, to reduce cardiovascular risk in adults with diabetes. The once-weekly dosing made it a major convenience step up from earlier daily and twice-daily agents.
Also: BI 456906
Survodutide is an injectable dual agonist that hits both the GLP-1 and glucagon receptors, developed by Boehringer Ingelheim and Zealand Pharma. It is being tested for obesity and for fatty liver disease (MASH), and it carries an FDA Breakthrough Therapy designation for MASH. It is still investigational and not approved for any use as of mid-2026.
Key Comparison Insights
- Dulaglutide is FDA approved, while Survodutide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Dulaglutide has stronger research evidence (FDA Approved) compared to Survodutide (Human Trials).
Detailed Comparison
| Attribute | Dulaglutide | Survodutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Dulaglutide activates the GLP-1 receptor, mimicking the natural incretin hormone your gut releases after eating. It prompts glucose-dependent insulin release, suppresses glucagon, and slows gastric emptying, so blood sugar drops after meals without driving dangerous lows. The antibody (Fc) portion bolted onto the peptide makes the molecule too large for the kidneys to quickly clear and shields it from the DPP-4 enzyme that destroys natural GLP-1 within minutes. That engineering is the entire reason a once-weekly schedule works. The appetite and modest weight effects come from the same GLP-1 signaling in brain regions that regulate hunger. | The drug works on two fronts at once. The GLP-1 receptor arm dampens appetite, slows how fast the stomach empties, and improves blood sugar handling, the same lever that semaglutide pulls. The glucagon receptor arm is the twist: glucagon signaling raises energy expenditure and pushes the liver to burn fat rather than store it. The idea, still being proven out in trials, is that adding controlled glucagon activity to GLP-1 action burns more energy and clears liver fat faster than a GLP-1 drug alone, which is why survodutide is aimed squarely at fatty liver disease. |
| Common Dosing | 1.5-4.5 mg weekly Once weekly | Limited community data available See research protocols |
| Administration | Subcutaneous injection weekly | Subcutaneous injection weekly |
| Typical Duration | Long-term / chronic use | Long-term use expected |
| Best Time to Take | Before bed or morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Dulaglutide is backed by extensive human trials, not animal models. The AWARD program established its glucose-lowering efficacy across many type 2 diabetes settings. The landmark REWIND trial, published in The Lancet in 2019, followed over 9,900 patients for a median of more than five years and was unusual because most participants (about 69%) had no prior cardiovascular disease. It found dulaglutide reduced major cardiovascular events (cardiovascular death, heart attack, or stroke) versus placebo, 12.0% vs 13.4%, a hazard ratio of 0.88. That made it one of the first GLP-1 agents with evidence supporting both primary and secondary cardiovascular prevention. The typical downsides are gastrointestinal (nausea, diarrhea), and like others in the class it carries a boxed warning about thyroid C-cell tumors based on rodent data. | This is one of the more advanced incretin dual agonists, and the human data are real, not hypothetical. In a Phase 2 MASH trial published in the New England Journal of Medicine in 2024 (Sanyal et al.), 293 biopsy-confirmed patients got weekly survodutide or placebo for 48 weeks, and MASH improved without worsening fibrosis in 47% of the 2.4 mg group and 62% of the 4.8 mg group, versus 14% on placebo. A separate Phase 2 obesity study showed weight loss up to roughly 18.7% at 46 weeks in completers. In April 2026, Boehringer Ingelheim and Zealand Pharma reported that the Phase 3 SYNCHRONIZE-1 obesity trial hit its mark with about 16.6% average weight loss. Large Phase 3 MASH trials (LIVERAGE and LIVERAGE-Cirrhosis) are ongoing. The catch worth knowing: nausea, vomiting, and other GI side effects are common, as with the whole incretin class, and final approval is not expected before 2027. |
Frequently Asked Questions: Dulaglutide vs Survodutide
What is the difference between Dulaglutide and Survodutide?
Dulaglutide is a weight loss peptide that dulaglutide (brand name trulicity) is a once-weekly injectable glp-1 receptor agonist made by fusing a modified glp-1 peptide to a fragment of a human antibody, which is what lets it last a full week between shots. it is fda-approved for type 2 diabetes and, notably, to reduce cardiovascular risk in adults with diabetes. the once-weekly dosing made it a major convenience step up from earlier daily and twice-daily agents. Survodutide is a weight loss peptide that survodutide is an injectable dual agonist that hits both the glp-1 and glucagon receptors, developed by boehringer ingelheim and zealand pharma. it is being tested for obesity and for fatty liver disease (mash), and it carries an fda breakthrough therapy designation for mash. it is still investigational and not approved for any use as of mid-2026. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Dulaglutide or Survodutide?
Neither is universally "better" - the choice depends on your specific goals. Dulaglutide is typically used for weight loss purposes, while Survodutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Dulaglutide and Survodutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Dulaglutide and Survodutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.